Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models

SIMPLE SUMMARY: Grade 4 gliomas and glioblastomas are the most common brain tumors, accounting for 50% of primary brain tumors, and the most aggressive, with a median 5-year patient survival of less than 10%. There is no therapy to date that can sustainably prolong the life of patients. In this work...

Descripción completa

Detalles Bibliográficos
Autores principales: Davy, Mélodie, Genest, Laurie, Legrand, Christophe, Pelouin, Océane, Froget, Guillaume, Castagné, Vincent, Rupp, Tristan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527257/
https://www.ncbi.nlm.nih.gov/pubmed/37760448
http://dx.doi.org/10.3390/cancers15184478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527257/
https://www.ncbi.nlm.nih.gov/pubmed/37760448
http://dx.doi.org/10.3390/cancers15184478

Ejemplares similares